At a glance
- Originator Inflabloc Pharmaceuticals
- Class Androstenols; Anti-inflammatories; Hormonal replacements; Small molecules
- Mechanism of Action Dehydroepiandrosterone replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Neurological disorders; Reperfusion injury
Most Recent Events
- 05 Dec 2003 No development reported - Preclinical for Neurological disorders in USA (Injection)
- 05 Dec 2003 No development reported - Preclinical for Reperfusion injury in USA (Injection)
- 25 Jan 2000 Preclinical development for Neurological disorders in USA (Injection)